Chronic Pain Syndromes

Chronic pain affects approximately 50 million Americans, with nearly 20 million experiencing high-impact chronic pain that substantially restricts life or work activities. Conditions such as complex regional pain syndrome (CRPS), fibromyalgia, neuropathic pain, chronic migraine, and phantom limb pain can be profoundly debilitating and often resistant to conventional treatments.

The standard approach to chronic pain management — NSAIDs, physical therapy, antidepressants, anticonvulsants, and opioids — provides adequate relief for many patients. However, a significant proportion remain undertreated, and the opioid epidemic has highlighted the urgent need for effective non-opioid pain therapies.

Ketamine has been used for pain management for decades in anesthetic settings and is now emerging as a powerful tool for refractory chronic pain conditions, particularly those involving central sensitization — a state where the nervous system amplifies pain signals beyond what the original injury would warrant.

Ketamine's pain-relieving properties work through multiple pathways:

• NMDA receptor antagonism: NMDA receptors play a central role in "wind-up" — the process by which the spinal cord and brain become increasingly sensitive to pain signals. By blocking these receptors, ketamine directly interrupts central sensitization, the core mechanism in many chronic pain conditions.
• Opioid receptor interaction: Ketamine has weak agonist effects at mu and kappa opioid receptors, contributing additional analgesic properties without the respiratory depression or constipation associated with traditional opioids.
• Anti-inflammatory effects: Ketamine reduces levels of pro-inflammatory cytokines and suppresses glial cell activation, both of which contribute to neuroinflammation and chronic pain perpetuation.
• Descending pain modulation: Ketamine enhances the brain's descending pain inhibitory pathways, strengthening the body's natural ability to modulate and suppress pain signals.
• Mood improvement: By concurrently improving depression and anxiety (common comorbidities of chronic pain), ketamine addresses the emotional amplification of pain.

Pain protocols differ significantly from mood disorder protocols:

• Higher doses: Pain-focused infusions typically use higher doses than mood disorder protocols, often ranging from 0.5–1.0 mg/kg/hour over 4–6 hours.
• Longer infusion times: While mood infusions typically last 40 minutes, chronic pain infusions may run for 4–8 hours, and some protocols use multi-day continuous infusions for severe CRPS.
• CRPS-specific protocols: For complex regional pain syndrome, intensive protocols involving daily infusions for 5–10 days or continuous infusions over several days have shown the most dramatic results.
• Maintenance: Pain patients often require maintenance infusions every 4–8 weeks. The frequency depends on the underlying condition and individual response.
• Multimodal approach: Ketamine for chronic pain is most effective as part of a comprehensive pain management plan that includes physical therapy, psychological support, and appropriate adjunctive medications.

Pain-specific safety considerations:

• Higher dose effects: Pain protocols use higher doses, which may produce more pronounced dissociative and psychotomimetic effects. Patients should be prepared for this possibility.
• Longer monitoring: Extended infusions require more prolonged cardiovascular monitoring and clinical oversight.
• Opioid tapering: Patients on chronic opioid therapy should work with their pain management team on gradual tapering schedules if ketamine allows dose reduction.
• Hepatic monitoring: For patients receiving frequent or high-dose ketamine infusions, periodic liver function testing is recommended.
• Urinary monitoring: Patients receiving high-dose or frequent infusions should be monitored for urinary symptoms, though bladder complications are rare at clinical doses.